Uzun etkili tipik ve atipik antipiskotiklerin iki uçlu bozukluk hastalarında kullanımı: Geriye dönük dosya taraması Amaç: İkiuçlu bozukluk (İUB) tanı ve tedavi sürecinde zorluklar içeren ve kronik seyir gösteren psikiyatrik bir bozukluktur. İUB idame tedavisinde en büyük sorunlardan biri ilaç uyumunun sağlanmasıdır. Uzun etkili enjektabl (UEE) antipsikotikler bu tür hastalarda ciddi avantajlar sağlamak-tadır. Biz bu çalışmada, tipik ve atipik UEE antipsikotikleri tedavi öncesi ve sonrasındaki bir yıllık dönemde klinik özellikler, hastane yatış sayıları ve yan etkiler açısından ayrı ayrı karşılaştırmayı amaçladık. Yöntem: Çalışma evreni Gaziantep Üniversitesi Duygudurum Birimi'nde takip edilen 802 İUB hastasından oluşturuldu. Bu hastalardan 80'i tipik ya da atipik UEE antipsikotik kullanıyordu. Çalışma kriterlerini karşılayan sadece 31 hasta çalışmaya dahil edildi. Etkinlik; tedavi öncesi ve sonrası bir yıllık dönem içindeki KGI, YMDÖ, HAMD skorları (12 ay önce, 6 ay önce, tedavi ekleme zamanı, 6 ay sonra ve 12 ay sonra), hastaneye yatış oranları ve ortalama yıllık hecme sayıları karşılaştırılarak değerlendirildi. Bulgular: Çalışma örnekleminde UEE antipsikotik kullanım oranı %9.88 olarak tespit edildi. İdame tedavide UEE antipsikotiklerin yıllık ortalama atak sayısını azalttığı ve depresyondan ziyade manik atağı önlemede etkin olduğu gösterildi. Atipik antipsikotiklerin YMDÖ ve KGI skorlarını anlamlı oranda azalttığı tespit edilirken HAMD skorlarında anlamlı bir değişiklik gözlenmedi. Tipik antipsikotikler ile ise ölçek skorlarının hiçbirinde anlamlı bir değişiklik görülmedi. Tipik ve atipik UEE antipsikotikler yan etkiler açısından tedavi öncesi ve sonrasında karşılaştırıldığında anlamlı bir farklılık saptanmadı. Tartışma: Çalışmamız bizim bilgilerimize göre, İUB'de atipik ve tipik UEE antipsikotiklerin birlikte dahil edildiği ilk çalışmadır. Sonuç olarak; UEE antipsikotiklerin manik atak korumasında etkin olabileceği ve yan etkiler açısından da tedavi öncesi ve sonrasında bir değişikliğin olmadığı göste-rilmiştir. Hasta sayısı artırılarak yapılacak yeni çalışmalarla çalışmamızın sonuçlarının tekrar edilmesine ihtiyaç vardır. Both typical and atypical long-acting injectable antipsychotics in bipolar disorder: a retrospective chart review Objective: Bipolar disorder (BD) is a chronic psychiatric disorder which shows difficulties in the process of diagnosis and treatment. One of the biggest problems in BD maintenance therapy is to ensure medication compliance. Long-acting injectable (LAI) antipsychotic medications have important advantages in such cases. In this study we aimed to include both LAI atypical and typical antipsychotics and to compare the clinical status, number of hospitalization, and side effects of pre and posttreatment periods of one year separately. Methods: Our study sample was constituted of 802 BD patients whom are followed in Mood Disorders Unit of Gaziantep University. Among them 80 patients has been using typical or atypical LAI antipsychotics. In the context of the study criteria only 31 patients included in the study. Efficacy was assessed by the CGI, YMRS, HAMD scores of pre and post-treatment periods of one year (12 months ago, 6 months ago, treatment initiation time, 6 months later and 12 months later), by the rate of hospitalization, and by comparing the average number of mood episodes. Results: LAI antipsychotic usage rate was identified as 9.88% in the study sample. Both of the antipsychotics were shown to decrease the average number of episodes in one year, and effective in preventing manic episodes rather than depressive episodes. Atypical antipsychotics significantly decreased YMRS and CGI scores but a decrease in HAMD scores was not observed, whereas no significant changes were observed in all scale scores with typical antipsychotics. There were not any significant difference when typical and atypical LAI antipsychotics compared according to their side effects in pre and post-treatment periods. Discussion: To the best of our knowledge, this is the first study that atypical and typical LAI antipsychotics were both included. As a result, it was shown that LAI antipsychotics may be effective in the prevention of manic episodes and there were not any differences found in terms of pre and post-treatment side effects. The results of our study are needed to be repeated in new studies with increased number of patients.
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INTRODUCTION
Bipolar disorder (BD) is a chronic psychiatric disorder which shows difficulties in the process of diagnosis and treatment (1) . In studies, lifetime prevalence is estimated to be 4.5% (1) . BD is a serious public health problem since it is widely seen with frequent relapses and recurrences causing high morbidity and high risk of suicide. Therefore it is the sixth disease leading to disability worldwide among those aged between 15-44 (2).
It has been reported that when BD patients left untreated, relapse rate exceeded 90% in the subsequent period of a manic episode (3, 4) whereas it exceeded 70% after a depressive episode (4, 5) . Although the maintenance treatment had been continued for 5 years, relapse rate was more than 70%. The most important reason was considered to be the partial or complete non-compliance to the treatment (4, 6) . Basically, treatment for BD is divided into two stages as acute and maintenance treatment. Maintenance therapy is important in preventing of recurrence, suicide, psychosocial outcomes of episodes, and comorbid disorders (alcohol and substance use disorders) after treatment of acute episodes (7) . Therefore, maintenance therapy should be planned beforehand with taking into consideration of the individual course of the illness. Existing data shows that the treatment in the acute phase would be also effective in the maintenance period (8) .
One of the biggest problems in maintenance therapy is to ensure medication compliance. Patient and family education, social skills training, supportive interventions, community-based interventions, cognitive behavioral therapy, and as well as long-acting injectable (LAI) antipsychotics take place in daily practice in order to improve compliance (9) . LAI antipsychotics have important advantages such as ensuring a stable blood level, reducing the risk of cessation of treatment, and preventing recurrences. Studies comparing the use atypical antipsychotics and mood stabilizers in maintenance therapy have not been revealed a significant difference in terms of efficacy (10, 11) . A study conducted with BD patients in our center showed that LAI risperidone was effective in reducing the symptoms of manic episode and preventing the recurrence (12) . Similarly in another study conducted with BD type I patients, LAI risperidone as maintenance therapy has shown to be effective to prevent the recurrence of manic episodes and it was indicated that it might increase the adherence to treatment (13) . Flupentixol decanoate, a typical antipsychotic, was shown to decrease the recurrence of manic episode when used as maintenance therapy (14) .
Considering these findings, antipsychotics nowadays have begun to be defined as mood stabilizers (10, 11) .
In this study we aimed to include both atypical and typical LAI antipsychotics and to compare the clinical status, number of hospitalization, and side effects of one year pre and post-treatment periods of one year separately.
METHOD
Our study population was constituted of 80 patients whom were diagnosed as BD I according to DSM-IV-TR and has been using LAI antipsychotics (zuclopenthixol decanoate, flupentixol decanoate, and risperidone) among 802 BD patients registered and followed in Mood Disorders Unit of Department of Psychiatry at Gaziantep University. The study was designed as retrospective chart review. The study inclusion criteria were defined as; using a LAI antipsychotic at least one year and continue followups regularly at least one year before and after LAI antipsychotic initiation, not having mental retardation, and not having any substance abuse or dependency. In the context of the inclusion criteria 49 patients were excluded from the study; 22 of them were lacking sufficient follow-up data for one year before the LAI antipsychotic initiation and 27 of them were lacking sufficient follow-up data for one year after the LAI initiation. Data of the study was created with only 31 patients meeting the study criteria. Efficacy was assessed by the CGI, YMRS, HAMD scores of one year before and after treatment initiation 
RESULTS
Sociodemographic characteristics are given in Table   1 . Patients' ages ranged from 22 to 62 (mean: 33.97±10.87).
26 patients (83.9%) were using atypical antipsychotics, 5 patients (16.1%) were using typical antipsychotics. At the beginning of LAI antipsychotic treatment, 25 patients (80.7%) were in manic episode, 3 (9.7%) were euthymic, 1 (3.2%) was in depressive episode, 1 (3.2%) was in mixed episode, and 1 (3.2%) was in hypomanic episode. The average dose in patients using LAI risperidone was 39.5±9.3 mg. The rate of hospitalization was found to be decreased 
DISCUSSION
In order to summarize the results of our study; (i) LAI antipsychotic usage rate was identified as 9.88% in the study sample, (ii) LAI antipsychotics as maintenance therapy were shown to decrease relapse rates in one year, In earlier studies, LAI antipsychotics had been shown to reduce and prevent mood episodes similar to the present study (12, 21, 22) . LAI risperidone was reported that it has a protective effect for manic episodes rather than depressive episodes (21) (22) (23) . The results of our study were consistent with the literature in this aspect and we also found that typical antipsychotics might have a similar effect. Indeed, flupentixol decanoate, has been shown to reduce the mean of yearly episodes in patients with predominantly manic episodes (24) .
There were no significant changes between pre and post-treatment scales with typical LAI antipsychotics were observed. Despite our study is the first study taking into consideration of changes in scales, the results of our study on this issue should be interpreted carefully since the small number of such patients (n=5). Possible explanations of this result may stem from preferring typical LAI antipsychotic treatment in patients with relatively higher YMRS scores than atypicals, and number of patients included in the study.
Atypical antipsychotics showed milder side effects (25) and reduced the rate of side effects after switching from typical to atypical antipsychotics (25) . In our study, the entire study sample showed no difference in terms of side effects before and after treatment even when evaluated according to the type of antipsychotic used. LAI antipsychotics, related with the technology that used in the production, are expected to be associated with lesser side effects than oral antipsychotics (26) .
The small number of patients treated with typical LAI antipsychotics may be accepted as a limitation of our study. Similar studies also included limited number of such patients and it has been shown that atypical antipsychotics were being preferred instead of typical antipsychotics day by day (27) . Retrospective design of the study and usage of CGI scores to assess the side effects instead of a specific scale may be accepted as other limitations.
CONCLUSION
To the best of our knowledge, this is the first study that atypical and typical LAI antipsychotics were both included. As a result, it was shown that LAI antipsychotics may be effective in the prevention of manic episodes and there were not any differences found in terms of pre and post-treatment side effects. The results of our study are needed to be repeated in new studies with increased number of patients.
